63 Documents the Government Doesn't Want You to Read

Copyright © 2011, 2021 by Jesse Ventura with Dick Russell

All Rights Reserved. No part of this book may be reproduced in any manner without the express written consent of the publisher, except in the case of brief excerpts in critical reviews or articles. All inquiries should be addressed to Skyhorse Publishing, 307 West 36th Street, 11th Floor, New York, NY 10018.

Skyhorse Publishing books may be purchased in bulk at special discounts for sales promotion, corporate gifts, fund-raising, or educational purposes. Special editions can also be created to specifications. For details, contact the Special Sales Department, Skyhorse Publishing, 307 West 36th Street, 11th Floor, New York, NY 10018 or info@skyhorsepublishing.com.

Skyhorse® and Skyhorse Publishing® are registered trademarks of Skyhorse Publishing, Inc.®, a Delaware corporation.

www.skyhorsepublishing.com

10 9 8 7 6 5 4 3 2 1

2021 Edition ISBN: 978-1-5107-5958-9

Library of Congress Cataloging-in-Publication Data

Ventura, Jesse.

63 documents the government doesn’t want you to read / Jesse Ventura, with Dick Russell.

p. cm.

Includes bibliographical references.

ISBN 978-1-61608-226-0 (alk. paper)

1. Official secrets--United States. 2. Government information--United States. 3. Government information--Access control--United States. 4. Conspiracies--United States. I. Russell, Dick. II. Title. III. Title: Sixty three documents the government doesn’t want you to read.

JK468.S4V46 2011

320.973--dc22

2011006218

Printed in the United States of America

To Congressman Ron Paul, the only federal elected official

who will stand up for America on the congressional floor.

CONTENTS

INTRODUCTION TO THE 2021 EDITION

FIVE NEW SCANDALOUS DOCUMENTS

1. The Virus Vaccine

2. Russian Interference in the 2016 Presidential Election

3. Who Really Ignited the Nationwide Protests?

4. Climate Change: The National Security Threat

5. Will Our Pentagon Finally Come Clean About UFOs?

Why You Need to Read This Book

PART ONE

OUR SCANDALOUS POSTWAR HISTORY

1. The CIA’s Secret Assassination Manual

2. U.S. Assassination Plots against Foreign Leaders

3. U.S. Public Health Service Exposed Guatemalan Prostitutes, Prisoners, Soldiers to Sexually Transmitted Disease

4 & 5 & 6. The CIA’s Project ARTICHOKE and MKULTRA

7. Operation Northwoods

8 & 9. Kennedy’s Plans to Withdraw Troops from Vietnam

10. What Really Happened at the Gulf of Tonkin

11. U.S. Capabilities in Chemical and Biological Warfare

PART TWO

GOVERNMENT, MILITARY, AND CORPORATE SECRETS

12. Putting War Criminals to Work for America

13 & 14 & 15. More on U.S. Intelligence and the Nazis

16. CIA Propaganda Notes on the Kennedy Assassination

17. Running Drugs with Dictators

18 & 19. America’s Blind Eye to Genocide

20. Military Experiments on Our Own Troops

21 & 22. Gulf War Illness and Our Veterans

23. Operation Garden Plot: Our Military and Civil Disturbances

24 & 25. Emergency Detention Camps and Civilian Inmate Labor Program

26. The Army’s Continuity of Operations Plan

27. The State Department Cable on Russia as a Mafia State

28. Our Food Supply Imperiled by Lack of Inspections

29. Pesticides and Honeybees

30. America’s Fight against Europe over Biotech Crops

31. Climate Change as a Threat to National Security

32. Koch Industries Seminars for the Rich and Powerful

PART THREE

SHADY WHITE HOUSES

33. Nixon’s Vietnam Peace Plan

34. Nixon’s Pursuit of the CIA’s Secret Files

35. How Nixon Wanted the CIA and FBI to Crack Down on Youthful Dissidence

36 & 37. The GES Emails and a CBS News Analysis

38 & 39. Fixing the Vote in Ohio

40. Hillary Clinton’s Call for Diplomats to Spy on the UN

41. An Internet Kill Switch?

42. Homeland Security’s Cybersecurity Agreement with the Pentagon

PART FOUR

9/11

43. A Think Tank’s Anticipation of 9/11

44. FBI Knowledge of Terrorists Training at Flight Schools

45. Bin Laden Determined to Strike in U.S., Bush Was Told

46. The Pentagon’s Stand Down Order on 9/11

47. The Free Fall of Building 7

48. Evidence for Insider Stock Trading Before 9/11

49. The FBI’s Briefing on Trading for the 9/11 Commission

PART FIVE

THE WAR ON TERROR

50. The Justice Department’s Secret Plan

51. President Bush’s Justification for Torture

52. The Military’s Astounding Media Ground Rules for Guantanamo

53 & 54. The Detainees at Guantanamo

55 & 56. A Medical Experiment on the Detainees

57 & 58 & 59. The Paper Trail on the CIA’s Destruction of 92 Torture Videos

60. Decapitation of a Detainee by U.S. Forces in Iraq

61. The State Department’s Take on Drug Money Leaving Afghanistan

62. A World Bank Report on Drugs

63. The Rand Report on Terrorism

EPILOGUE

Resources for Curious Readers

63 DOCUMENTS THE

GOVERNMENT DOESN’T

WANT YOU TO READ

INTRODUCTION TO THE 2021 EDITION

It has been a decade since this book first came out and became a New York Times bestseller. We’ve been through the Obama years and now we’ve got Donald Trump. I’m still out there calling for a third-party alternative, and I seriously thought about entering the 2020 race as an independent candidate. People are hungry for a straight shooter, and I like to think I qualify as one We sure can’t say that secrets and lies aren’t the prevailing wisdom among our political leaders. Fake news wasn’t even in our lexicon ten years ago, and now it’s even harder to know what’s real and what’s a fabrication or straight-out lie. Walter Cronkite used to help us make an informed decision, and today we’ve got a thousand pundits competing for our attention on TV and social media. It’s no longer about truth, but instead ratings and clickbait headlines.

So I’ve decided it’s time for an updated edition of 63 Documents the Government Doesn’t Want You to Read. The historical perspective that the first edition of this book provided is more relevant than ever. But what I want to do here is bring you up to speed on some of the most important issues of our time as we enter the third decade of the twenty-first century.

You’ll read about one of the companies involved in the race for a COVID-19 vaccine; about how the Russians used social media to influence the last election; about how climate change is considered a high-level national security threat by our own military; about how the Trump administration has covered up the truth about white supremacists, instigating the protests against racial injustice; and about what the Pentagon doesn’t want us to know about UFO sightings and the projects in its Advanced Aerospace Threat and Identification Program (AATIP).

I hope these documents—kicking off this new edition—will help serve as a wake-up call to our citizenry in a world increasingly out of the pages of George Orwell. We can’t afford to pretend any longer that ignorance is strength.

THE VIRUS VACCINE

By the time this book comes out, there may already be a vaccine for the COVID-19 virus. One of the three companies in the race to make this happen is Moderna, based in Cambridge, Massachusetts. There are, however, some very strange things about this outfit. Firstly, they’ve never produced a vaccine. Secondly, they were on the verge of bankruptcy until Bill Gates and Anthony Fauci stepped in with funding.

We’ll start with a shocking paragraph in Moderna’s vaccine patent application in 2019, about the possibility of a deliberate release of coronavirus. This ties right into reports our intelligence agencies were looking into: that COVID-19 might have escaped from the lab in Wuhan, China, where it was created.

The main document about Moderna looks at the fact that the company never revealed any of the grant money it was receiving from the Pentagon’s Defense Advanced Research Project Agency (DARPA), The RNA vaccine it’s developing has never been made before. And guess what? It’s designed to alter your genes.

KEI Series on inventors that fail to disclose U.S. government funding in patented inventions

1. Introduction

This research note examines apparent failures to disclose U.S. federal government funding of the inventions claimed in several patents assigned to Moderna Therapeutics (Moderna). It focuses on awards from the Defense Advanced Research Projects Agency (DARPA).

While similar issues can be raised regarding funding of Moderna from other agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH), this note focuses on the role of DARPA. KEI will publish a different research note examining the reporting of R&D funding by BARDA and the NIH.

The obligation to disclose U.S. federal government support in patent applications is a requirement of the Bayh-Dole Act and regulations issued by the U.S. Patent and Trademark Office.

Moderna was one of the awardees under the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program and performed research related to mRNA vaccines with funds granted by DARPA. Moderna used the ADEPT funding in their Chikungunya and Zika vaccines programs. It is likely that the DARPA awards more generally supported the establishment of their mRNA platform, which can be used against other viral infections, including COVID-19. This support is acknowledged by DARPA itself, for instance on the DARPA website it currently has a statement stating [t]he first coronavirus vaccine to start human testing is from DARPA investment in the Moderna company.¹

Several of the patents filed by Moderna since March 22, 2013 (when their first grant from DARPA was awarded), claim inventions related to methods and compositions for inducing an immune response by administering an mRNA vaccine. Some of these patents are specifically related to their Chikungunya and Zika vaccines programs, some are directed to vaccines against other viral infections, and others are generally relevant to the mRNA platform Moderna has developed.

2 of 25

KEI Series on inventors that fail to disclose U.S. government funding in patented inventions

KEI examined the 126 patents assigned to Moderna or ModernaTx as well as 154 patent applications. Despite the evidence that multiple inventions were conceived in the course of research supported by the DARPA awards, not a single one of the patents or applications assigned to Moderna disclose U.S. federal government funding.

2. DARPA backed mRNA vaccines research early on

Messenger RNA (mRNA) is a ribonucleic acid (RNA) molecule complementary to one of the deoxyribonucleic acid (DNA) strands of a gene.² mRNA serves as an intermediary that carries the genetic information of a DNA molecule to the cell machinery responsible for protein synthesis.³ Due to this role as an intermediary, mRNA has been considered for years as a candidate for prophylactic and therapeutic applications. One of the potential mRNA applications is in vaccine development. Conventional vaccines usually contain inactivated pathogens that mimic the infectious agent. When administered, they stimulate an immune response. In mRNA-based vaccines, however, no pathogens are introduced. Rather, the instructions on how to produce an immune response are encoded in mRNA and provided to a subject.

Some scientists have been advocating for the use of mRNA as a vaccine platform for years.⁴ One of the key benefits of mRNA in vaccine development is flexibility. In principle, any protein can be encoded and expressed by mRNA; this, in theory, enables the development of a wide range of therapeutic and prophylactic applications. Another key feature is safety. Because mRNA is non-infectious, there is no potential risk of infection or insertional mutagenesis.⁵

Successful use of mRNA in vivo to elicit a physiological response has been reported since the early 1990s.⁶ However, despite promising results, these findings did not lead to substantial private investment towards developing mRNA therapeutics largely due to concerns associated with mRNA instability, high innate immunogenicity and inefficient in vivo delivery.⁷ It took decades before using mRNA as a vaccine platform became an attractive approach for private investors. Nevertheless, at a time when private investors were still skeptical about mRNA, DARPA made an early push in support of this approach to vaccine development. Starting in 2011, the agency allocated millions